Efficacy and Safety of Pembrolizumab in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.

Cancer InvestJun 5, 2026 (epub)
Clinical ResearchOncology (Medical)Gastroenterology

Kunhong Tang, Wei Zheng Huang, Jiaqi Wei et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of pembrolizumab in 4,560 patients with advanced gastric cancer. The study found that pembrolizumab significantly improved overall survival and objective response rate compared to control treatments, although progression-free survival showed no significant difference. Importantly, pembrolizumab did not increase the risk of treatment-related death (OR = 0.99, 95% CI 0.59-1.65).

Key findings

  • Pembrolizumab significantly improved overall survival and objective response rate compared to control treatments.
  • No significant difference in progression-free survival was observed.
  • The risk of treatment-related death was comparable to chemotherapy (OR = 0.99, 95% CI 0.59-1.65).
  • Combination therapy showed superior efficacy but higher immune-related toxicity.

Why it matters

The findings provide important insights into the safety and efficacy of pembrolizumab, addressing concerns about immunotherapy in advanced gastric cancer. Understanding the benefits and risks can guide treatment decisions and improve patient outcomes.

Source

PubMed · PMID 42246227

Published in Cancer Invest. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.